ZUKANORM 100SR TAB

About

Zukanorm 100SR is a sustained-release formulation of Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, indicated for the treatment of type 2 diabetes mellitus. This extended-release tablet is designed to provide a prolonged therapeutic effect, ensuring consistent blood glucose control throughout the day. Vildagliptin works by inhibiting the DPP-4 enzyme, which is responsible for the breakdown of incretin hormones, GLP-1 and GIP. By preserving these endogenous hormones, Zukanorm 100SR enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon release from alpha cells, thereby effectively reducing both fasting and postprandial hyperglycemia. The sustained-release mechanism aims to improve patient compliance by allowing for once-daily dosing while maintaining stable drug levels. It is typically used as an adjunct to diet and exercise, either as monotherapy or in combination with other antidiabetic agents, to achieve optimal glycemic targets.

Uses

• Management of type 2 diabetes mellitus.
• Improvement of glycemic control in adults.
• Used as an adjunct to diet and exercise.
• As monotherapy or in combination therapy.

Directions For Use

Take this medication orally as directed by your physician, usually once daily. Swallow the tablet whole; do not crush, chew, or break it.

Benefits

• Provides sustained blood glucose control.
• Enhances natural insulin secretion.
• Reduces glucagon levels.
• Convenient once-daily dosing.
• Low risk of hypoglycemia when used alone.
• Generally well-tolerated.

Side Effects

• Headache
• Dizziness
• Nasopharyngitis
• Upper respiratory tract infection
• Cough
• Constipation
• Diarrhea
• Nausea
• Peripheral edema
• Arthralgia
• Pancreatitis (rare)
• Skin reactions

Safety Measures

• Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake should be avoided as it may affect blood sugar levels.
• Pregnancy - Consult your doctor. This medication is generally not recommended during pregnancy unless clearly necessary, as its safety has not been fully established.
• Breastfeeding - Consult your doctor. It is unknown if Vildagliptin passes into breast milk, and its use during breastfeeding should be carefully considered.
• Liver - Use with caution in patients with liver impairment. Liver function tests should be monitored before and during treatment.
• Kidney - Use with caution and dose adjustment in patients with kidney impairment. Your doctor will determine the appropriate dosage.
• Lung - No specific contraindications, but general health should be considered.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.